Your browser doesn't support javascript.
Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies.
Cao, Xia; Maruyama, Junki; Zhou, Heyue; Fu, Yanwen; Kerwin, Lisa; Powers, Colin; Sattler, Rachel A; Manning, John T; Singh, Alok; Lim, Reyna; Healy, Laura D; Johnson, Sachi; Paz Cabral, Elizabeth; Li, Donghui; Lu, Lucy; Ledesma, Arthur; Lee, Daniel; Richards, Susan; Rivero-Nava, Laura; Li, Yan; Shen, Weiqun; Stegman, Karen; Blair, Benjamin; Urata, Shinji; Kishimoto-Urata, Magumi; Ko, Jamie; Du, Na; Morais, Kyndal; Lawrence, Kate; Rivera, Ianne; Pai, Chin-I; Bresson, Damien; Brunswick, Mark; Zhang, Yanliang; Ji, Henry; Paessler, Slobodan; Allen, Robert D.
  • Cao X; Sorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
  • Maruyama J; Galveston National Laboratory, Department of Pathology, University of Texas Medical Branch, Galveston, TX, 77555, USA.
  • Zhou H; Sorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
  • Fu Y; Sorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
  • Kerwin L; Sorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
  • Powers C; Sorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
  • Sattler RA; Galveston National Laboratory, Department of Pathology, University of Texas Medical Branch, Galveston, TX, 77555, USA.
  • Manning JT; Galveston National Laboratory, Department of Pathology, University of Texas Medical Branch, Galveston, TX, 77555, USA.
  • Singh A; Sorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
  • Lim R; Sorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
  • Healy LD; Sorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
  • Johnson S; Sorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
  • Paz Cabral E; Sorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
  • Li D; Sorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
  • Lu L; Sorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
  • Ledesma A; Sorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
  • Lee D; Sorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
  • Richards S; Sorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
  • Rivero-Nava L; Sorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
  • Li Y; Sorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
  • Shen W; Sorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
  • Stegman K; Sorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
  • Blair B; Sorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
  • Urata S; Galveston National Laboratory, Department of Pathology, University of Texas Medical Branch, Galveston, TX, 77555, USA.
  • Kishimoto-Urata M; Galveston National Laboratory, Department of Pathology, University of Texas Medical Branch, Galveston, TX, 77555, USA.
  • Ko J; Sorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
  • Du N; Sorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
  • Morais K; Sorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
  • Lawrence K; Sorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
  • Rivera I; Sorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
  • Pai CI; Sorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
  • Bresson D; Sorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
  • Brunswick M; Sorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
  • Zhang Y; Sorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
  • Ji H; Sorrento Therapeutics, Inc., San Diego, CA, 92121, USA. hji@sorrentotherapeutics.com.
  • Paessler S; Galveston National Laboratory, Department of Pathology, University of Texas Medical Branch, Galveston, TX, 77555, USA. SLPAESSL@utmb.edu.
  • Allen RD; Sorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
Sci Rep ; 12(1): 15517, 2022 09 15.
Article in English | MEDLINE | ID: covidwho-2028729
ABSTRACT
Coronavirus disease 2019 (COVID-19) continues to significantly impact the global population, thus countermeasure platforms that enable rapid development of therapeutics against variants of SARS-CoV-2 are essential. We report use of a phage display human antibody library approach to rapidly identify neutralizing antibodies (nAbs) against SARS-CoV-2. We demonstrate the binding and neutralization capability of two nAbs, STI-2020 and STI-5041, against the SARS-CoV-2 WA-1 strain as well as the Alpha and Beta variants. STI-2020 and STI-5041 were protective when administered intravenously or intranasally in the golden (Syrian) hamster model of COVID-19 challenged with the WA-1 strain or Beta variant. The ability to administer nAbs intravenously and intranasally may have important therapeutic implications and Phase 1 healthy subjects clinical trials are ongoing.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Prognostic study Topics: Variants Limits: Animals / Humans Language: English Journal: Sci Rep Year: 2022 Document Type: Article Affiliation country: S41598-022-19780-7

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Prognostic study Topics: Variants Limits: Animals / Humans Language: English Journal: Sci Rep Year: 2022 Document Type: Article Affiliation country: S41598-022-19780-7